infigratinib 0.128 mg/kg/day
QBGJ398-304
Phase 3 small_molecule active
Quick answer
infigratinib 0.128 mg/kg/day for Hypochondroplasia is a Phase 3 program (small_molecule) at BridgeBio Oncology Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BridgeBio Oncology Therapeutics
- Indication
- Hypochondroplasia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active